Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders [1][3] - The company granted equity awards to two new non-executive employees as an inducement for employment, consisting of stock options and restricted stock units (RSUs) [1][2] Equity Awards Details - The equity awards include stock options for 240,000 shares and 150,000 RSUs, with the stock options having an exercise price of $0.94, equal to the closing price on the grant date [2] - Stock options vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting quarterly thereafter; RSUs vest in four equal installments on each anniversary of the grant date [2] Company Pipeline - Opus Genetics is developing AAV-based gene therapies targeting inherited retinal diseases such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa [3] - The lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown promising early results [3] - Additional programs include OPGx-BEST1 for BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances [3]

Core Points - Orion Energy Systems, Inc. announced the authorization of equity awards for Michael Ontrop, the new Senior Vice President of Channel Sales, including 100,000 shares of restricted stock and a non-qualified stock option for 125,000 shares of Common Stock [1][2] - The equity awards were approved by Orion's Board of Directors as a material inducement for Mr. Ontrop to accept the employment offer, and the shares will not be drawn from the 2016 Omnibus Incentive Plan [2] - The restricted stock award will vest one-third on each of the first three anniversaries of the grant date, contingent on Mr. Ontrop's continued employment [3] - The stock option will vest based on the Company's share price reaching specified levels ($3.00, $4.00, and $5.00) over a three-year period, with the effective grant date set for July 18, 2025 [4] Company Overview - Orion Energy Systems specializes in energy efficiency and clean tech solutions, including LED lighting, EV charging solutions, and maintenance services [5] - The company focuses on turnkey design-through-installation solutions for large national customers and projects through ESCO and distribution partners, aiming to help customers achieve business and environmental goals [5] - Orion is committed to operating responsibly and emphasizes sustainability and governance in its operations [6]

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 In ...

Core Points - TELA Bio, Inc. announced the approval of an inducement grant of stock options and restricted stock units to Jim Hagen, the Senior Vice President of Strategic Commercial Operations, as part of his employment compensation [1][2] - The stock options have an exercise price of $1.42 per share, with a ten-year term and a vesting schedule over four years [2] - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's own anatomy [3] Summary by Category Inducement Grant Details - The Compensation Committee approved an option to purchase 75,000 shares and restricted stock units covering 30,000 shares for Jim Hagen [1] - The stock options will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following 36 months [2] - The restricted stock units will vest in equal annual installments over four years [2] Company Overview - TELA Bio is a commercial-stage medical technology company [3] - The company aims to provide advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response [3] - TELA Bio minimizes long-term exposure to permanent synthetic materials in its solutions [3]